REFERENCES
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-49.
2. Imyanitov EN, Iyevleva AG, Levchenko EV. Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives. Crit Rev Oncol Hematol. 2021;157:103194.
3. Duffy MJ, O’byrne K. Chapter One - Tissue and blood biomarkers in lung cancer: a review. Adv Clin Chem. 2018;86:1-21.
4. Shi JF, Wang L, Wu N, et al. Clinical characteristics and medical service utilization of lung cancer in China, 2005-2014: overall design and results from a multicenter retrospective epidemiologic survey. Lung Cancer. 2019;128:91-100.
5. Osmani L, Askin F, Gabrielson E, Li QK. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy. Semin Cancer Biol. 2018;52:103-9.
7. Thakur MK, Gadgeel SM. Predictive and prognostic biomarkers in non-small cell lung cancer. Semin Respir Crit Care Med. 2016;37:760-70.
8. Duan B, Bai J, Qiu J, et al. Histone-lysine N-methyltransferase SETD7 is a potential serum biomarker for colorectal cancer patients. EBioMedicine. 2018;37:134-43.
9. He A, Bai J, Huang C, et al. Detection of serum tumor markers in multiple myeloma using the CLINPROT system. Int J Hematol. 2012;95:668-74.
10. Risha Y, Minic Z, Ghobadloo SM, Berezovski MV. The proteomic analysis of breast cell line exosomes reveals disease patterns and potential biomarkers. Sci Rep. 2020;10:13572.
11. Tsuchida S, Satoh M, Takiwaki M, Nomura F. Current status of proteomic technologies for discovering and identifying gingival crevicular fluid biomarkers for periodontal disease. Int J Mol Sci. 2018;20:86.
12. Murphy S, Zweyer M, Mundegar RR, Swandulla D, Ohlendieck K. Proteomic serum biomarkers for neuromuscular diseases. Expert Rev Proteomic. 2018;15:277-91.
13. Geyer PE, Holdt LM, Teupser D, Mann M. Revisiting biomarker discovery by plasma proteomics. Mol Syst Biol. 2017;13:942.
14. Kisluk J, Ciborowski M, Niemira M, Kretowski A, Niklinski J. Proteomics biomarkers for non-small cell lung cancer. J Pharm Biomed Anal. 2014;101:40-9.
15. Zhu Z, Zhang W, Huo S, Huang T, Cao X, Zhang Y. TUBB, a robust biomarker with satisfying abilities in diagnosis, prognosis, and immune regulation via a comprehensive pan-cancer analysis. Front Mol Biosci. 2024;11:1365655.
16. Mariani M, Karki R, Spennato M, et al. Class III β-tubulin in normal and cancer tissues. Gene. 2015;563:109-14.
17. Yu X, Zhang Y, Wu B, Kurie JM, Pertsemlidis A. The miR-195 axis regulates chemoresistance through TUBB and lung cancer progression through BIRC5. Mol Ther Oncolytics. 2019;14:288-98.
18. Yeh IT, Ludueña RF. The betaII isotype of tubulin is present in the cell nuclei of a variety of cancers. Cell Motil Cytoskeleton. 2004;57:96-106.
19. Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov. 2010;9:790-803.
20. Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer. 2010;10:194-204.
21. Bouras G, Nakanishi T, Fujita Y, Tsunemi S, Takubo T, Tanigawa N. Identification of β-tubulin as a common immunogen in gastrointestinal malignancy by mass spectrometry of colorectal cancer proteome: implications for early disease detection. Anal Bioanal Chem. 2012;403:1801-9.
22. He Q, Peng B, Zhuang D, et al. Clinicopathological significance of β-tubulin isotype III gene expression in breast cancer patients. Cancer Biomark. 2015;15:823-31.
23. Zhao X, Yue C, Chen J, et al. Class III β-tubulin in colorectal cancer: tissue distribution and clinical analysis of chinese patients. Med Sci Monit. 2016;22:3915-24.
24. De Donato M, Mariani M, Petrella L, et al. Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer. J Cell Physiol. 2012;227:1034-41.
25. Fan NJ, Kang R, Ge XY, et al. Identification alpha-2-HS-glycoprotein precursor and tubulin beta chain as serology diagnosis biomarker of colorectal cancer. Diagn Pathol. 2014;9:53.
26. Sève P, Reiman T, Dumontet C. The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer. Lung Cancer. 2010;67:136-43.
27. Maahs L, Sanchez BE, Gupta N, et al. Class III β-tubulin expression as a predictor of docetaxel-resistance in metastatic castration-resistant prostate cancer. PLoS One. 2019;14:e0222510.
28. Ruksha K, Mezheyeuski A, Nerovnya A, et al. Over-expression of βII-tubulin and especially its localization in cell nuclei correlates with poorer outcomes in colorectal cancer. Cells. 2019;8:25.
29. Gao J, Zhang L, Peng K, Sun H. [Diagnostic value of serum tumor markers CEA, CYFRA21-1, SCCAg, NSE and ProGRP for lung cancers of different pathological types]. Nan Fang Yi Ke Da Xue Xue Bao. 2022;42:886-91.
